Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;29(9):4931-4937.
doi: 10.1007/s00520-021-06124-w. Epub 2021 Mar 12.

Supportive oncodermatology-a narrative review of its utility and the way forward

Valencia Long  1 , Ellie Ci-En Choi  2 , Chris Lixian Tan  2
Affiliations
Review

Supportive oncodermatology-a narrative review of its utility and the way forward

Valencia Long et al. Support Care Cancer. 2021 Sep.

Abstract

Supportive oncodermatology is an interdisciplinary field, emerging due to increasing dermatological morbidity in patients with cancer and the recognition of the need for greater collaborative and integrated care to improve patient outcomes. These two unique fields (Oncology and Dermatology) may be integrated in various ways, such as through specialised combined clinics, protocols for expedited access, multidisciplinary groups and meetings, and the development of best practices guidelines. This narrative review consolidates the small but growing literature surrounding supportive oncodermatology; discusses the potential benefit and disadvantages, and areas for future research; and suggests a framework for implementation.

Keywords: Cutaneous toxicities; MASCC; Supportive care; Supportive oncodermatology.

PubMed Disclaimer

References

    1. Phillips GS, Freites-Martinez A, Wu J, Chan D, Fabbrocini G, Hellmann MD, Lacouture ME (2019) Clinical characterization of immunotherapy-related pruritus among patients seen in 2 oncodermatology clinics. JAMA Dermatology 155(2):249–251. https://doi.org/10.1001/jamadermatol.2018.4560 - DOI
    1. Giuliani J, Bonetti A (2016) The pharmacological costs for the management of skin toxicity in patients with cancer treated with epidermal growth factor receptor-inhibitors. Clin Lung Cancer 17(6):471–473. https://doi.org/10.1016/j.cllc.2016.04.006 - DOI
    1. Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W, Sehouli J (2008) Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study. Support Care Cancer 16(3):267–273. https://doi.org/10.1007/s00520-007-0318-8 - DOI
    1. Schnur JB, Graff Zivin J, Mattson DMK Jr, Green S, Jandorf LH, Wernicke AG, Montgomery GH (2012) Acute skin toxicity-related, out-of-pocket expenses in patients with breast cancer treated with external beam radiotherapy: a descriptive, exploratory study. Support Care Cancer 20(12):3105–3113. https://doi.org/10.1007/s00520-012-1435-6 - DOI - PubMed - PMC
    1. Lowe KA, Sangaré L, Bergstresser R, McNamara M, Kafatos G, Garawin T (2019) A national survey of medical oncologist’s opinions and perceptions for managing rash among mCRC patients treated with panitumumab. Dermatol Ther 9(2):337–353. https://doi.org/10.1007/s13555-019-0296-z - DOI

LinkOut - more resources